Gal-9-mediated immunosuppression could be overcome by anti-Gal-9 blockade, which enhanced chimeric antigen receptor (CAR) T cell therapeutic responses in PDA patients [199]. This evidence concerns the gene LGALS9 and Patent ductus arteriosus.